No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LTH240621C20000
- 0.09
- +0.01+12.50%
15min DelayClose May 31 11:12 ET
0.09High0.09Low
0.09Open0.08Pre Close2 Volume26 Open Interest20.00Strike Price18.00Turnover55.15%IV19.73%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.09Time Value100Contract SizeAmericanOptions Type0.0955Delta0.0802Gamma186.44Leverage Ratio-0.0095Theta0.0008Rho17.80Eff Leverage0.0065Vega
Intraday
- 5D
- 1D
News
Life Time to Participate in June Investor Conferences
CHANHASSEN, Minn., May 31, 2024 /PRNewswire/ -- Life Time Group Holdings, Inc. ("Life Time" or the "Company") (NYSE: LTH) today announced the Company will participate in three upcoming investor confe
Life Time Group Holdings, Inc.'s (NYSE:LTH) P/E Is Still On The Mark Following 27% Share Price Bounce
The Life Time Group Holdings, Inc. (NYSE:LTH) share price has done very well over the last month, posting an excellent gain of 27%. Unfortunately, the gains of the last month did little to right th
Life Time Group Holdings: A Balanced Hold Rating Amidst Financial and Operational Challenges
Analysts Offer Insights on Consumer Cyclical Companies: Norwegian Cruise Line (NCLH), Kohl's (KSS) and Life Time Group Holdings (LTH)
Buy Rating Affirmed: Life Time Group's Innovative Adaptability and Growth Prospects
Life Time Group Holdings Insiders Added US$2.54m Of Stock To Their Holdings
Comments
The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Is There Now An Opportunity In Life Time Group Holdings, Inc. (NYSE:LTH)? 1
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
$Life Time(LTH.US$ another good earnings yet they dumped it. Trash market.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
$Life Time(LTH.US$ New trend line confirmed? Higher lows with 3 touch points now on the 5 min chart
Read more